国际放射医学核医学杂志
國際放射醫學覈醫學雜誌
국제방사의학핵의학잡지
INTERNATIONAL JOURNAL OF RADIATION MEDICINE AND NUCLEAR MEDICINE
2009年
2期
86-88
,共3页
肿瘤转移%骨肿瘤%锶放射性同位素%153Sm-乙二胺四亚甲基膦酸
腫瘤轉移%骨腫瘤%鍶放射性同位素%153Sm-乙二胺四亞甲基膦痠
종류전이%골종류%송방사성동위소%153Sm-을이알사아갑기련산
Neoplasm metastasis%Bone neoplasms%Strontium radioisotopes%153Sm-ethylene diamihe tetramethylene phosphonic acid
目的 对比研究89SrCl2和153Sm-乙二胺四亚甲基膦酸(153Sm-EDTMP)治疗骨转移癌疗效.方法 120例骨转移患者随机分为89SrCl2治疗组和153Sm-EDTMP治疗组,分别为69例和51例,89SrCl2剂量为1.11～2.22 MBq/Kg,153Sm-EDTMP剂量为25.9～37.0 MBq/kg,3～6月复查SPECT,对止痛效果、转移灶变化及不良反应进行比较分析.结果 89SrCl2组总有效率、显效、有效、无效分别为92.8%、69.6%、23.3%、7.2%;153Sm-EDTMP组的总有效率、显效、有效、无效分别为94.2%、66.7%、27.5%、5.8%,两组比较的差异无统计学意义(X2=4.98,P>0.05);89SrCl2治疗组骨转移病灶Ⅰ级(变淡,缩小或消失,无新增病灶出现)为56.5%,153Sm-EDTMP组为54.9%,两组比较的差异无统计学意义(X2=4.81,P>0.05);骨髓抑制情况(白细胞和血小板中任一项降低)分别为40.8%和59.2%,两组比较的差异有统计学意义(X2=7.45,P<0.05).结论 153Sm-EDTMP和89SrCl2控制乳腺癌、前列腺癌及大多数肺癌骨转移疼痛有效,可根据经济条件选择相应药物.89SrCl2疗效持久,相对骨髓抑制较小,更安全可靠,可作为早期骨转移患者的首选药物.
目的 對比研究89SrCl2和153Sm-乙二胺四亞甲基膦痠(153Sm-EDTMP)治療骨轉移癌療效.方法 120例骨轉移患者隨機分為89SrCl2治療組和153Sm-EDTMP治療組,分彆為69例和51例,89SrCl2劑量為1.11～2.22 MBq/Kg,153Sm-EDTMP劑量為25.9～37.0 MBq/kg,3～6月複查SPECT,對止痛效果、轉移竈變化及不良反應進行比較分析.結果 89SrCl2組總有效率、顯效、有效、無效分彆為92.8%、69.6%、23.3%、7.2%;153Sm-EDTMP組的總有效率、顯效、有效、無效分彆為94.2%、66.7%、27.5%、5.8%,兩組比較的差異無統計學意義(X2=4.98,P>0.05);89SrCl2治療組骨轉移病竈Ⅰ級(變淡,縮小或消失,無新增病竈齣現)為56.5%,153Sm-EDTMP組為54.9%,兩組比較的差異無統計學意義(X2=4.81,P>0.05);骨髓抑製情況(白細胞和血小闆中任一項降低)分彆為40.8%和59.2%,兩組比較的差異有統計學意義(X2=7.45,P<0.05).結論 153Sm-EDTMP和89SrCl2控製乳腺癌、前列腺癌及大多數肺癌骨轉移疼痛有效,可根據經濟條件選擇相應藥物.89SrCl2療效持久,相對骨髓抑製較小,更安全可靠,可作為早期骨轉移患者的首選藥物.
목적 대비연구89SrCl2화153Sm-을이알사아갑기련산(153Sm-EDTMP)치료골전이암료효.방법 120례골전이환자수궤분위89SrCl2치료조화153Sm-EDTMP치료조,분별위69례화51례,89SrCl2제량위1.11～2.22 MBq/Kg,153Sm-EDTMP제량위25.9～37.0 MBq/kg,3～6월복사SPECT,대지통효과、전이조변화급불량반응진행비교분석.결과 89SrCl2조총유효솔、현효、유효、무효분별위92.8%、69.6%、23.3%、7.2%;153Sm-EDTMP조적총유효솔、현효、유효、무효분별위94.2%、66.7%、27.5%、5.8%,량조비교적차이무통계학의의(X2=4.98,P>0.05);89SrCl2치료조골전이병조Ⅰ급(변담,축소혹소실,무신증병조출현)위56.5%,153Sm-EDTMP조위54.9%,량조비교적차이무통계학의의(X2=4.81,P>0.05);골수억제정황(백세포화혈소판중임일항강저)분별위40.8%화59.2%,량조비교적차이유통계학의의(X2=7.45,P<0.05).결론 153Sm-EDTMP화89SrCl2공제유선암、전렬선암급대다수폐암골전이동통유효,가근거경제조건선택상응약물.89SrCl2료효지구,상대골수억제교소,경안전가고,가작위조기골전이환자적수선약물.
Objective To evaluate the effect of 89SrCl2 and 153Sm-ethylenediaminetetramethylene phosphonate (153Sm-EDTMP) on metastatic carcinoma of bone. Methods All patients with widespread metastatic bone cancers were divided into two groups randomly: sixty-nine patients were treated with 89SrCl2 with dose of 1.11～2.22 MBq/kg by intravenous injection, fifth-one patients were treated with 153Sm-EDTMP with dose of 25.9～37.0 MBq/kg by the same way. Bone imaging was analized in 3～6 months. The pain, the metastasis varied situation, and side-effect were compared. Results In the group of 89SrCl2 the remission rats of bone pain of positive response, total-effect, apparent, finess, no-effect was 92.8%, 69.6%, 23.3%, 7.2% respectively. In the group of 153Sm-EDTMP, the data were 94.2%, 66.7%, 27.5%, 5.8% respectively. There were not significantly different between groups of 89SrCl2 and 153Sm-EDTMP (X2=4.98, P>0. 05). In group of 89SrCl2 the rate of area of skeletal metastases Grade Ⅰ (disappear, reduction, maintain and no-new-development) was 56.5%. However it was, in 153Sm-EDTMP group, 54.9%. There was no significantly difference between 89SrCl2 and 153Sm-EDTMP groups (X2=4.81, P>0.05). The arrest rate of bone marrow (white blood or blood platelet was descended) of 89SrCl2 group was 40.8% while in 153Sm-EDTMP group was 59.2%. There was a significantly different between them (X2=7.45, P<0.05). Conclusion 89SrCl2 and 153Sm-EDTMP have effect on metastatic carcinoma of bone treatment. It is suggested that one can choose each of them by economic condition. But, 89SrCl2 can maintain the effect in a long time and bone marrow is arrested serious, so it is the first choise for early metastatic carcinoma of bone.
